Vanta Bioscience Limited reported standalone and consolidated audited earnings results for the half year and full year ended March 31, 2019. For the half year, on standalone basis, the company reported revenue from operations of INR 64.026 million against INR 34.925 million a year ago. Total revenue was INR 65.558 million against INR 35.453 million a year ago. Net Profit from ordinary activities after tax was INR 4.008 million against loss of INR 0.236 million a year ago. Earnings per basic and diluted share (before and after extra ordinary items) was INR 0.77 against INR 0.0 a year ago. For the year, on standalone basis, the company reported revenue from operations of INR 124.248 million against INR 29.86 million a year ago. Total revenue was INR 126.536 million against INR 40.388 million a year ago. Net Profit from ordinary activities after tax was INR 6.938 million against INR 0.273 million a year ago. Earnings per basic and diluted share (before and after extra ordinary items) was INR 1.17 against INR 0.05 a year ago. For the half year, on consolidated basis, the company reported revenue from operations of INR 64.606 million. Total revenue was INR 66.1455 million. Net Profit from ordinary activities after tax was INR 4.035 million. Earnings per basic and diluted share (before and after extra ordinary items) was INR 0.78. For the year, on consolidated basis, the company reported revenue from operations of INR 124.828 million against INR 39.860 million a year ago. Total revenue was INR 127.1235 million against INR 40.388 million a year ago. Net Profit from ordinary activities after tax was INR 6.965 million against INR 0.273 million a year ago. Earnings per basic and diluted share (before and after extra ordinary items) was INR 1.19 against INR 0.05 a year ago.